Abbott Labs Still Unvervalued, Now Less Threatened by Lawsuit
YCharts.com submits: Increasingly, as goes Humira, a drug that treats rheumatoid arthritis and other immune systems disorders, so goes Abbott Laboratories (ABT), and so news earlier this week that a federal appeals court had tossed out a $1.67 billion patent-infringement judgment against Abbott made the company’s shares all that more attractive. YCharts Pro finds Abbott undervalued, with strong fundamentals, and the pharmaceutical maker pays an ever-rising dividend, having hiked the payout February 18 for the 39th consecutive year. The quarterly dividend goes to 48 cents, from 44, funded by Abbott’s steadily rising profit.
Investor neglect of the shares has pushed the dividend yield past 4%. Abbott 2010 sales rose 14.3% to $35.2 billion, and Humira, with a 19.3% jump to $6.5 billion, was pushing the growth.
The company has also boosted R&D spending, and made acquisitions financed by borrowings, to keep the growth going. That has raised its debt-to-equity ratio.
But Humira,Complete Story »